Designation of Recombinant Factor IX (FIXTERA) as an Orphan Drug - Baxter Healthcare Pty Ltd

Overview

The designation of recombinant factor IX (FIXTERA) as an orphan drug under the Therapeutic Goods Regulations 1990 was enacted to address the need for specialised treatment options for rare diseases, specifically haemophilia B, a congenital disorder characterised by a deficiency in factor IX. This legislative action was taken on the 3rd of October, 2012, by Dr Anthony Gill, acting as the Delegate of the Secretary, pursuant to the authority granted by subregulation 16J (2) of the Regulations. The primary aim of this designation is to facilitate the development and availability of orphan drugs, which are crucial for treating rare medical conditions that might otherwise lack sufficient research and treatment options due to their limited patient populations. This initiative underscores the commitment to addressing the healthcare needs of individuals affected by rare diseases in Australia.

Scope and Application

The Designation of recombinant factor IX (FIXTERA) as an orphan drug under the Therapeutic Goods Regulations 1990 applies specifically to the medical treatment product FIXTERA, which is a form of recombinant factor IX designated for the treatment of patients with haemophilia B, also known as congenital factor IX deficiency or Christmas disease. This designation is intended to address the control and prevention of haemorrhagic episodes and to provide routine and surgical prophylaxis for this condition. The designation was made on 3rd October 2012 by Dr Anthony Gill, the Delegate of the Secretary, under subregulation 16J(2) of the Regulations. The sponsor of this orphan drug is Baxter Healthcare Pty Ltd. The scope of this legislation is confined to the therapeutic use of recombinant factor IX (FIXTERA) for the specified medical condition, and it does not extend to other drugs or medical conditions. The geographic and jurisdictional reach of this designation is primarily within Australia, as it operates under the Australian Commonwealth's Therapeutic Goods Regulations 1990. There are no exclusions, exemptions, or thresholds explicitly stated in the text. The application of this legislation may be further extended or clarified through subordinate instruments or subsequent regulatory actions, although no such provisions are mentioned in the text itself.

Key Provisions

The key operative sections of this legislation (C2012G00074) designate recombinant factor IX (FIXTERA) as an orphan drug for the treatment of haemophilia B, effective from 3rd October 2012 (section 1). This designation is made under subregulation 16J(2) of the Therapeutic Goods Regulations 1990 (section 2). The drug, FIXTERA, is specified for use in controlling and preventing haemorrhagic episodes, and for routine and surgical prophylaxis in patients suffering from haemophilia B, which is also known as congenital factor IX deficiency or Christmas disease (section 3). The mode of administration for this treatment is intravenous injection (section 4), and the sponsor of the drug is Baxter Healthcare Pty Ltd (section 5). Under this legislation, the primary obligation imposed on the parties involved is the proper classification and use of FIXTERA as an orphan drug. This classification acknowledges the rarity of the condition it treats and facilitates specific regulatory support and incentives. The sponsor, Baxter Healthcare Pty Ltd, must ensure that the drug is manufactured, labelled, and distributed in compliance with the Therapeutic Goods Regulations 1990. These regulations cover aspects such as quality, safety, efficacy, and proper labelling of therapeutic goods. The sponsor must also ensure that any clinical trials and post-market surveillance align with the regulatory standards to maintain the orphan drug status and the therapeutic benefits for patients. There are no explicit offences, penalties, or consequences for breach detailed in the text of this particular legislation. However, any failure to comply with the Therapeutic Goods Regulations 1990 could result in enforcement actions by the Therapeutic Goods Administration (TGA), which may include fines, product recalls, or other regulatory sanctions. The penalties for breaches of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can be severe, including substantial fines and potential criminal charges for serious offences. The maximum penalties for contravening the regulations can extend to fines of up to $1,215,000 for corporations and $243,000 for individuals, depending on the severity and nature of the breach. Therefore, adherence to the regulatory requirements is critical for the sponsor and any parties involved in the distribution and use of FIXTERA.